FLXN Flexion Therapeutics, Inc.

+0  (2%)
Previous Close 20.60
Open 20.43
Price To book 3.49
Market Cap 664.45M
Shares 31,731,000
Volume 2,816,538
Short Ratio 6.45
Av. Daily Volume 593,092

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date October 6, 2017.
Zilretta - FX006
Osteoarthritis of the knee
Phase 2 top-line data released November 2016.
Zilretta - FX006
Osteoarthritis of the knee with type 2 adult diabetes

Latest News

  1. Flexion Therapeutics Highlights Two Clinical Data Presentations at the Osteoarthritis Research Society International 2017 World Congress
  2. Flexion Therapeutics Announces Pricing of $175 Million 3.375% Convertible Senior Notes due 2024
  3. Why Flexion Therapeutics Inc. Stock Is Tanking
  4. Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka
  5. Flexion Therapeutics Announces Proposed Convertible Senior Notes Offering
  6. Flexion Therapeutics to Report First-Quarter 2017 Financial Results on May 4, 2017
  7. Why Flexion Therapeutics' New Pain Drug Could Be a Game-Changer
  8. Can Drugmakers Cure the Opioid Crisis?
  9. Shark Bites: You Don't Want to Play the Gambler Today
  10. ​Sanofi Genzyme exec jumps to Flexion amid buyout rumors
  11. Sanofi Buying Flexion: A Smart Move?
  12. Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer
  13. Flexion Therapeutics Announces Issuance of Two New Patents Further Strengthening Intellectual Property Protection (IP) for Zilretta™ (FX006)
  14. 3 Revolutionary Drugs for Chronic Pain
  15. Flexion Therapeutics to Present at Needham & Company’s 16th Annual Healthcare Conference
  16. How I'd Play Biotech Buyout Rumors
  17. Sanofi Could Acquire This Biotech, But Is $1 Billion Too Low?
  18. Advances in Healthcare Technology and Osteoarthritis Drug Therapies Propel Two Healthcare Stocks
  19. Did Sanofi Just Bag This Biotech For $1 Billion?
  20. Here's Why Flexion Therapeutics Inc. Skyrocketed Today